Impressions and Response to Chelation Therapy Trial
Feb 01, 2013 04:13PM
By Dr. Conrad G. Maulfair, Jr.
Chelation Therapy is an effective, safe, comprehensive program that can benefit people with chronic degenerative diseases. People with conditions like heart disease, diabetes, arthritis, lack of energy and problems of aging can experience a resurgence of energy and life quality. This program is not new. It has been studied and offered to patients by many progressive physicians to hundreds of thousands of thankful people worldwide for over 60 years. Patients who receive chelation therapy experience their quality of life improve first hand. The doctors who provide individualized programs enjoy their observations of their patients’ improvements.
It makes our day that we are no longer alone in these observations; the United States government via the National Institutes of Health (NIH) funded a study on chelation therapy. The study called TACT, Trial to Assess Chelation Therapy, started in 2003. The positive results were just announced at the American Heart Association’s meeting, November 4, 2012.
People in this trial who received chelation therapy had decreased hospitalizations for angina, compared to the control group. There were fewer deaths from heart attacks and strokes for the patients receiving chelation therapy. The chelation patients also needed less bypass surgeries and angioplasties; the findings were especially positive for patients who also suffered from diabetes. Chelation therapy reduced cardiac events by 18 percent and by 39 percent for diabetic patients. The total reduction in cardiac events was statistically significant.
Physicians conducting the study included university cardiologists and experienced chelation physicians. Keep in mind that all study participants had a previous heart problem before beginning the trial—83 percent had either bypass surgeries, angioplasty with or without stents. The majority of participants had high blood pressure and 73 percent had been prescribed cholesterol-lowering statin drugs. One thousand seven hundred people participated in the study. An additional finding was the unquestionable safety of chelation therapy.
Considering the decreased need for angioplasty and bypass surgery it wouldn’t be surprising to see the cardiology and cardiovascular surgeons less than enthusiastic about the study results.
Those of us who have been trained to provide chelation therapy for the benefit of our patients have known for many years the wide range of improvement possible for our patients. Through thick and thin our care has been without support in the main from mainstream medicos so we welcome scientific evidence from a large clinical trial confirming some of the many benefits we have observed in our patients.
Truth be told, however, if the study was not positive, I would have continued to provide chelation therapy to my patient family and continued my own chelation program. After 40 years of providing this care in clinical practice, I know the benefits. I see PVD, heart disease, high blood pressure, and diabetes abate all the time. Some of our diabetic patients no longer require insulin injections.
Although I have been providing the therapy for many years, I chose not to be one of the participating physicians. I understand the significance the majority of the medical profession places on the double blind study protocol and was uncomfortable in treating any patient with a placebo. Those physicians that did participate are to be commended and we owe them a debt of gratitude, as well as the patient patient participants. Kudos to all who continue the good fight for what is right.
Maulfair Medical Center is located at 2970 Corporate Ct., Ste. 1, in Orefield. For more information, call 610-682-2104 or visit DrMaulfair.com or ICEM.com.